The commentary starts by suggesting that our article contradicts major professional guidelines. It omits to mention that the NCCN recommendation is flagged as involving "major NCCN disagreement that the intervention is appropriate". The guideline from the European Society for Medical Oncology is out of date; the most recent guideline1 does not include prostate-specific antigen (PSA) velocity in localized disease. The third reference given is a website of an educational nonprofit, in which the only reference to PSA velocity is a patient guide from 2010.
展开▼
